A researcher from UTMB has partnered with a major research institute to help detect new, potential drug compounds for use against highly pathogenic agents and their effects. Bersabeh Tigabu is working with the Southern Research Institute to jointly develop a semi-automated, high-throughput screening system for pathogenic agents. The screening process consists of a proprietary platform used in drug discovery, which is capable of testing 10,000 compounds each day through the use of robotics, data processing, and control software. The organization notes that the new screen system can be used at biosafety level 4 biocontainment conditions in order to identify active compounds, antibodies, or genes for a starting point of drug design. Their latest development was published in the journal ASSAY and Drug Development Technologies.